Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
10.4%
Period ended Sep 30, 2026
Change on a year earlier
+1.1 pts
9.3% in Q3 2025
History
35 quarters
Since Q1 2018
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 10.4% | +1.1 pts | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 10.0% | +4.3 pts | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 22.9% | +26.6 pts | SEC Filing (0001628280-26-025365) ↗ |
| Q4 2025 | Dec 31, 2025 | 13.4% | +5.2 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 9.3% | +3.6 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 5.7% | +5.3 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | -3.7% | -12.7 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 8.2% | -6.3 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 5.7% | -2.5 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 0.4% | -9.9 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 9.0% | +12.2 pts | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | 14.5% | +27.8 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 8.2% | +19.8 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 10.3% | +14.7 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q1 2023 | Mar 31, 2023 | -3.2% | -2.4 pts | SEC Filing (0001628280-23-012020) ↗ |
| Q4 2022 | Dec 31, 2022 | -13.3% | -18.8 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -11.6% | -26.9 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -4.4% | -41.6 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | -0.8% | -14.2 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | 5.5% | +3.4 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 15.3% | +18.0 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 37.2% | +58.5 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | 13.4% | +19.8 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | 2.1% | -0.7 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | -2.7% | -6.9 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | -21.3% | -17.5 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | -6.4% | -0.9 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 2.8% | +9.2 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | 4.2% | +6.2 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -3.8% | -4.3 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -5.5% | -13.8 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | -6.4% | – | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | -2.0% | – | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 0.5% | – | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 8.3% | – | SEC Filing (0001104659-18-024701) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Rhythm Management Division (Aveir Leadless Pacemaker, Gallant ICD, Assert-IQ ICM) International — Reported Sales Growth (%) (%), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-rm-yoy-rep-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.